Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.

ABSTRACT:

Background/aims

The optimal duration of nucleos(t)ide analogs (NAs) therapy in chronic hepatitis B (CHB) patients remains unsatisfactory. Previous studies have confirmed the important role of host genetic factors in determining the outcome of HBV infection. This study tries to determine the role of host genetic factors in predicting response status in CHB patients discontinuing NAs according to stringent cessation criteria.

Patients and methods

Participating patients came from a prospective NAs- discontinuation cohort since June 1999. Six single-nucleotide polymorphisms (SNPs) were selected according to previous report. SNaPshot assay was used for DNA SNPs analyses.

Results

Seventy-six CHB patients were enrolled in our study, of which 61 patients were HBeAg-positive a

SUBMITTER: Li T 

PROVIDER: S-EPMC5848322 | biostudies-literature | 2018 Jan-Feb

REPOSITORIES: biostudies-literature